Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00044057 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate the Effects of YM872 on Brain Function and Disability When Administered in Combination With Alteplase (Tissue Plasminogen Activator)
A Phase 2 study of Acute Ischemic Stroke, sponsored by Astellas Pharma.
- Completed
- Registry status
- Phase 2
- Development phase
- 20
- Study locations
NCT00044057 is a Phase 2 study of Acute Ischemic Stroke that has completed, run by Astellas Pharma. The trial reports 20 study locations across 4 states.
The verdict
NCT00044057, a Phase 2 study of Acute Ischemic Stroke, has completed, sponsored by Astellas Pharma.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 20
- Study locations
Study Summary
The purpose of this study is to determine if YM872 in combination with t-PA can reduce disability and brain damage from stroke. YM872 or placebo will be given as a continuous intravenous (iv) infusion for 24 hours. It is important that the study medication, YM872 or placebo, is administered prior to the completion of the t-PA administration. The clinical effects of YM872 in addition to t-PA will be determined by assessing neurological function and disability scores at follow up visits through Day 90 of the study.
Conditions Studied
Interventions
- DRUG YM872 (zonampanel), t-PA (alteplase)
Study Locations (20)
California
- East Bay Region Associates in Neurology - Berkeley
- Providence St. Joseph's Medical Center - Burbank
- Mercy San Juan Hospital - Carmichael
- University of California Davis Medical Center - Davis
- Scripps Memorial Hospital - Encinitas
- Grossmont Hospital - La Mesa
- UCLA Medical Center - Los Angeles
- Tri-City Medical Center - Oceanside
- Stanford University Medical Center - Palo Alto
- Mercy General Hospital - Sacramento
- Scripps Mercy Hospital - San Diego
- University of California at San Diego - San Diego
- Good Samaritan Hospital - San Jose
- UCLA Medical Center - Santa Monica - Santa Monica
- John Muir Medical Center - Walnut Creek
- Mt Diablo Medical Center - Walnut Creek
Arizona
- Good Samaritan Hospital - Phoenix
- University of Arizona - Tucson
Alabama
- University of South Alabama Stroke Center - Mobile
Colorado
- Colorado Neurological Institute - Englewood
Trial Details
| Field | Value |
|---|---|
| Start Date | 2000-12 |
| Est. Completion | 2003-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00044057
The ClinicalTrials.gov registry entry for NCT00044057 describes a study currently listed as completed, categorized as Phase 2. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Astellas Pharma, which has 165 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Acute Ischemic Stroke appearing as the primary indexed condition, and to 1 intervention - of which YM872 (zonampanel), t-PA (alteplase) is the first listed.
NCT00044057 reports 20 study locations spanning 4 distinct geographic areas - top geographies include California, Arizona, Alabama.
Frequently Asked Questions
What is clinical trial NCT00044057 about?
NCT00044057 is a clinical study titled "A Study to Evaluate the Effects of YM872 on Brain Function and Disability When Administered in Combination With Alteplase (Tissue Plasminogen Activator)". The purpose of this study is to determine if YM872 in combination with t-PA can reduce disability and brain damage from stroke. YM872 or placebo will be given as a continuous intravenous (iv) infusion for 24 hours. It is important that the study medication, YM872 or placebo, is administered prior to...
What is the current status of trial NCT00044057?
This trial is currently completed. It is a Phase 2 study. The study started on 2000-12. Estimated completion is 2003-01.
What conditions does trial NCT00044057 study?
This clinical trial studies the following conditions: Acute Ischemic Stroke.
What interventions are being tested in trial NCT00044057?
The interventions under investigation include: YM872 (zonampanel), t-PA (alteplase) (DRUG).
Who is sponsoring clinical trial NCT00044057?
This trial is sponsored by Astellas Pharma, which has 165 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00044057 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Acute Ischemic Stroke
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Transcranial Direct Current Stimulation for Treatment of Acute Ischemic Stroke
RECRUITING · Phase 2
-
Optimizing Reperfusion to Improve Outcomes and Neurologic Function
RECRUITING · Phase 2
-
A Study to Evaluate the Safety and Efficacy of LT3001 Drug Product in Subjects AIS Undergoing EVT
RECRUITING · Phase 2
-
Study of BB-031 in Acute Ischemic Stroke Patients (RAISE)
RECRUITING · Phase 2
-
A Phase 2b, Randomized, Double-blind Study of Redasemtide (S-005151) in Adult Participants With Acute Ischemic Stroke
ACTIVE NOT RECRUITING · Phase 2
-
A Study to Evaluate the Safety and Potential Efficacy of LT3001 Drug Product in Subjects With AIS
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.